MRKR Stock — Marker Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.18

Market cap

$19.7M

Cash

$11.3M

Enterprise value

$8.4M

Balance sheet

Cash	$11.3M
Debt	$0.0M
Net cash	$11.3M
Enterprise value	$8.4M
Basic shares	16.7M shares
Fully diluted shares	26.1M shares
Fully diluted market cap	$30.8M
Cash per share	$0.68

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MRKR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 10 - May 22	MT-601	Phase 1	Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Refractory; Non-Hodgkin Lymphoma, Relapsed	—
Aug 27 - Oct 8	MT-601 dose 200 million cells	Phase 1	Pancreas Cancer; Pancreatic Cancer Metastatic; Pancreatic Cancer (Unresectable)	—
Oct 13 - Nov 24	MT-401-OTS	Phase 1	Acute Myeloid Leukemia, in Relapse; MDS	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MT-601

Phase 1 · Active Modality: cell therapy (autologous multi-antigen-recognizing MAR-T cells, non-genetically engineered)

Target NY-ESO-1 / PRAME / MAGE-A4 / Survivin / WT1 / SSX2

Partnerships Baylor College of Medicine (BCM): exclusive license to MAR-T technology ($5M equity; up to $64.85M milestones; tiered royalties). Grants: CPRIT $13.1M (AML, now shifted), CPRIT $9.5M (pancreatic), NIH SBIR $2M (NHL) + $2M (pancreatic PANACEA), FDA Orphan grant $2M, DoW $4.2M (LBCL, Jul 2026)

Indications

Lymphoma (B-cell, relapsed after anti-CD19 CAR-T or CAR-T ineligible) (Phase 1)
Pancreatic cancer (metastatic) (Phase 1)

Catalysts

— 2026

Status note Lead program. Phase 1 APOLLO in lymphoma: 24 patients (15 NHL, 9 HL) with objective responses and favorable safety (update Aug 2025, cutoff Jun 2025). Technology-transfer/manufacturing SOW with Cellipont signed Jun 2025 for pivotal-trial scale-up.

MT-401-OTS

Phase 1 · Active Modality: cell therapy (off-the-shelf MAR-T cells)

Aliases MT-401

Target WT1 / NY-ESO-1 / PRAME / Survivin

Partnerships BCM license (as MT-601); CPRIT/FDA/NIH grants agreed to shift funds to MT-401-OTS

Indications

Acute myeloid leukemia (AML, post-transplant / post-HMA) (Phase 1)
Myelodysplastic syndromes (MDS) (Stage not disclosed)

Status note Off-the-shelf MAR-T program; funders (CPRIT $13.1M, FDA Orphan $2M, NIH SBIR $2M) shifted support from MT-401 to MT-401-OTS.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	MT-601
Lead indication	Non-Hodgkin Lymphoma, Adult
Lead phase	Phase 1
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05798897	Phase 1	Recruiting	Sponsor	MRKR	—	Non-Hodgkin Lymphoma, Adult; Non-Hodgkin Lymphoma, Refractory; Non-Hodgkin Lymphoma, Relapsed	—
NCT06549751	Phase 1	Not yet recruiting	Sponsor	MRKR	—	Pancreas Cancer; Pancreatic Cancer Metastatic; Pancreatic Cancer (Unresectable)	—
NCT06552416	Phase 1	Recruiting	Sponsor	MRKR	—	Acute Myeloid Leukemia, in Relapse; MDS	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Marker Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

MRKR — Marker Therapeutics Inc.